Menu
Search
|

Menu

Close
X

Tigenix NV TIG.OQ (NASDAQ Stock Exchange Global Select Market)

41.98 USD
-- (--)
As of Jul 26
chart
Previous Close 41.98
Open --
Volume --
3m Avg Volume 296
Today’s High --
Today’s Low --
52 Week High 47.59
52 Week Low 20.59
Shares Outstanding (mil) 296.07
Market Capitalization (mil) 522.99
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, EUR)
FY17
0
FY16
25
FY15
2
EPS (EUR)
FY17
-0.283
FY16
0.012
FY15
-0.211
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
--
15.43
Price to Book (MRQ)
vs sector
22.80
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
116.75
14.84
LT Debt to Equity (MRQ)
vs sector
21.50
11.13
Return on Investment (TTM)
vs sector
-105.02
12.77
Return on Equity (TTM)
vs sector
-148.10
14.47

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Box 2, Romeinse Straat 12
HEVERLEE     3001

Phone: +3216.396060

TiGenix NV is a Belgium-based biopharmaceutical company focused on the development and commercialization of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells. The Company's two products from the adipose-derived stem cell platform are in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn’s disease patients, and Cx611 which has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. From the Company's cardiac stem cell-based platform are AlloCSC-01 with a Phase II clinical trial in Acute Myocardial Infarction, and AlloCSC-02 being developed for a chronic indication. TiGenix NV operates in the domestic market and in Madrid, Spain.

SPONSORED STORIES